Background: Biphosphonate use is expected to increase Bone Mineral Density (BMD) and reduce the risk of vertebral and non-vertebral fractures. This may also lead to an improvement of Health Related Quality of Life (HR QoL) in the treated patients.

Objectives: To confirm the efficacy and safety of 1 year oral Ibandronate, 150 mg monthly. To analyze its effect on patients' quality of life.

Methods: 140 postmenopausal patients (average age 65.2 yrs, avg age of menopause 46.8 yrs, avg years from menopause 18.3yrs) diagnosed with osteoporosis (T-score <2.5 SD) during 2014 – 2015, were given 150mg of oral Ibandronic Acid monthly and supplements of Calcium and Vitamin D daily. BMD was measured with DXA HOLOGIC at baseline and after 1 year of treatment. HR QoL was assessed through EQ – VAS at baseline and after 1 year.

Results: 132 patients completed the study. 5 patients (3.5%) withdrew from the study because of G-I complications, 3 patients (2.1%) did not repeat the DXA. A statistically significant increase of BMD was noted in the lumbar spine, (4.7%, p<0.001) and in the hip region (2.9%, p<0.001). Patients' perceived health also improved on a Visual Analogue Scale. Median 74 IR 60: 89 compared to median 70 IR 51:86 at the beginning of the study.

Conclusions: Oral Ibandronate is safe and effective in increasing BMD in both Hip and lumbar spine. Apart from reducing the risk of fractures, it helps to improve the patients' perceived Health Related Quality of Life.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2016-eular.4856